From March 13 to 14, the 2026 International Oncology & Embolization Physician Advisory Board Meeting (2026 IO&E SAB) was held in Minnesota, USA. The meeting brought together 24 leading experts from around the world to explore cutting-edge technologies and jointly shape the future of the field.
In recognition of his profound expertise in minimally invasive cancer therapies and his strong international reputation, President Niu Lizhi of Guangzhou Fuda Cancer Hospital was invited to attend as one of five representatives from Asia. During the meeting, he engaged in in-depth discussions and academic exchanges with top scholars from the United States, Europe, and across Asia, focusing on the latest advancements in interventional oncology and tumor ablation. He also shared valuable insights drawn from China’s clinical experience, combining practical expertise with innovative thinking.
△ President Niu Lizhi with Professor Matthew from Mayo Clinic, recalling their interaction and photo at the WCIO conference 10 years ago
△ President Niu Lizhi with Professor Koichiro Yamakado, President of the Japan Radiological Society
△ President Niu Lizhi discussing the development of cryoablation technology with a technical expert from Boston Scientific
Academic progress knows no borders, and collaboration drives innovation. This SAB meeting was not only a platform for exchanging cutting-edge knowledge, but also an opportunity to deepen international cooperation. President Niu’s participation reflects the growing global recognition of China’s advancements in minimally invasive cancer treatment. Through this platform, a strong and confident “China voice” was shared with the world, highlighting the capabilities of Chinese medical institutions in the field of interventional oncology and ablation.
“Through in-depth exchanges with leading experts worldwide, we have gained a more comprehensive understanding of the latest developments and future trends in cancer diagnosis and treatment,” said President Niu. “We will integrate these cutting-edge insights into our clinical practice, striving to provide more advanced technologies and higher-quality care to better safeguard the lives and health of every cancer patient.”